Wednesday, December 4, 2019

Everbridge Selected to Power Countrywide Disaster Alert Platform in Peru for 37 Million Residents and Annual Visitors

 Peru Win Reinforces Everbridge’s Global Leadership in Population Alerting with Countrywide Contracts in the Americas, EMEA, and APAC regions



BURLINGTON, Mass.-Wednesday 4 December 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management, today announced it has been selected by Peru’s Ministry of Transportation and Communications (MTC) to power the nation’s Sistema de Mensajería de Alerta Temprana de Emergencia (Sismate), Peru’s Early Warning Emergency Messaging System. The news marks the completion of contract negotiations with the MTC that Everbridge had initially disclosed in September, without naming the country. The win reinforces Everbridge’s position as the global leader in population warning systems with contracts in the Americas, EMEA, and APAC regions.

After the Sismate is deployed, it will be activated once Peru’s National Institute of Civil Defense detects a major incident. The system, powered by Everbridge Public Warning, will send critical messages to mobile phones before, during and after the emergency. Sismate alerts can also be used in drills and to provide support in search and rescue operations. The Sismate is designed to serve over 37 million people including Peru’s 33 million residents and 4 million annual visitors.

“This technology marks a milestone in risk and disaster management at the national level, which will be consolidated by combining joint efforts between various institutions and citizens,” explained Deputy Minister of Communications Virginia Nakagawa to El Economista.

“Everbridge is honored to support Peru with its national warning system,” said David Meredith, Chief Executive Officer at Everbridge. “Peru joins a growing number of countries that have chosen to partner with Everbridge to implement a nationwide system to protect their population and visitors amid an escalating threat environment.”

The Everbridge Platform has been deployed by more local, state, and national governments across the globe than any other solution, offering the ability to reach over 500 million people in more than 200 countries. In addition to Peru, Everbridge Public Warning has been deployed to reach the mobile populations on a country-wide scale in Sweden, Iceland, the Netherlands, Singapore, Greece, and a number of the largest states in India, and is currently being implemented in Australia. Everbridge is the first population alerting provider to support four EU countries in conjunction with the recent EU mandate requiring member countries to have a population-wide alerting system in place by June 2022.

Everbridge Public Warning represents the only multichannel solution which allows countries to deploy their preferred combination of emergency communications methods. The Everbridge population warning system communicates across all phases of an incident, leverages location intelligence (static location, last known location, and expected location), provides directed two-way communications, and enables countries to combine both speed of delivering alerts with the broadest reach to cover the full population and visitors.

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 4,800 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 2.8 billion messages in 2018 and offers the ability to reach over 500 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Sweden, the Netherlands, Singapore, Greece, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center®, Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 9 of the 10 largest U.S. cities, 8 of the 10 largest U.S.-based investment banks, 46 of the 50 busiest North American airports, 6 of the 10 largest global consulting firms, 6 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 5 of the 10 largest U.S.-based health insurers. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Beijing, Bangalore, Kolkata, London, Munich, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com, read the company blog, and follow on LinkedIn, Twitter, and Facebook.

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to successfully integrate businesses and assets that we may acquire; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 1, 2019. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005296/en/

Contacts

Media:
Jim Gatta
Everbridge
jim.gatta@everbridge.com
215-290-3799

Jeff Young
Everbridge
jeff.young@everbridge.com
781-859-4116



Permalink : https://www.aetoswire.com/news/everbridge-selected-to-power-countrywide-disaster-alert-platform-in-peru-for-37-million-residents-and-annual-visitors/en

Tuesday, December 3, 2019

Moody’s Analytics Experts Release New Book on Future of Credit Risk

Credit Risk Measurement and Management: Disruption and Evolution, edited by Amnon Levy and Jing Zhang, traces the evolution of credit risk management, with contributions from economist Nouriel Roubini, KMV and DCI co-founder Stephen Kealhofer, Prudential CRO Nick Silitch, and other leading thinkers.




SAN FRANCISCO-Tuesday 3 December 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Moody’s Analytics, a leading provider of financial intelligence, today announced the release of Credit Risk Measurement and Management: Disruption and Evolution, edited by Moody’s Analytics experts Dr. Amnon Levy, Head of Portfolio and Balance Sheet Research, and Dr. Jing Zhang, Global Head of Research and Modeling. Other Moody’s Analytics experts contributing to the book include Dr. Douglas Dwyer, Dr. Tony Hughes, Dr. Ashit Talukder, Elaine Wong, and Dr. Pierre Xu.

Published by Risk Books, this book includes 15 chapters representing a broad selection of perspectives from key thinkers and practitioners involved in credit risk management. Contributors hail from regulatory bodies, banks, insurance companies, consulting firms, analytics providers, and fintech disruptors. Their contributions explore the intersection of technology, regulatory mandates, and geopolitical developments, and form conclusions about the business and operational impacts of each.

”Over the last few decades, regulatory oversight, information-technology advances, and political events have driven unprecedented levels of change in credit risk management,” said Levy. “Organizations will need to understand the interplay among these forces to manage credit risk effectively both now and in the coming years.”

“The future of credit risk management will be marked by seemingly intractable new challenges, including climate change and global debt,” added Zhang. “But by studying the evolution of credit risk management to this point, institutions will be better prepared to handle these threats going forward.”

Click here to learn more about the book or to purchase a copy.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.

Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 44 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005145/en/

Contacts
GENE KIM
Moody’s Analytics Communications
+1.415.874.6013

Moody’s Analytics Media Relations

moodysanalytics.com
twitter.com/moodysanalytics
linkedin.com/company/moodysanalytics




Permalink : https://www.aetoswire.com/news/moodyrsquos-analytics-experts-release-new-book-on-future-of-credit-risk/en

Gen Re and PAI Health Take Strategic Partnership to Next Level

Exclusivity agreement demonstrates joint commitment to bringing pioneering digital heart health technology to insurance community.

STAMFORD, Conn.-Tuesday 3 December 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Decades of evidence have proven cardiorespiratory fitness to be a leading predictor of longevity and future health. Yet it is one that has been largely overlooked within insurance customer health profiles. With the signing of the exclusive agreement between leading global reinsurer, Gen Re, and health technology software company, PAI Health, this is set to change.

PAI Health is known for its innovation in biometric sensing and algorithm development with unique data insights rooted in cardiorespiratory fitness. The company’s digital services are based on published research that has demonstrated the effectiveness of the heart rate-based metric called Personal Activity Intelligence (PAI) in recommending personalized activity levels for optimal mortality risk reduction from cardiovascular disease and other lifestyle diseases.

Over the past 18 months, Gen Re and PAI Health have been working together to tailor the PAI proposition for the insurance sector. Together, they have now begun showcasing its potential to Gen Re’s clients around the world, with a view to using PAI’s potential to drive customer engagement and explore new ways of assessing risk.

Commenting on the agreement, Winfried Heinen, Head of Gen Re Life/Health International, said: “We meet many insurtech companies with promising ideas but PAI Health stood out from the start due to the scientific rigour behind their solution. We have no doubt about the value PAI holds for the insurance community, both in terms of acquisition and engagement, and ultimately helping consumers lead longer and healthier lives.”

Vincent DeMarco, Head of Gen Re’s North American Life/Health Division, added: “The signing of this agreement demonstrates our mutual commitment to bringing PAI Health’s pioneering mHealth technology to insurance. We look forward to working closely with them to build on the momentum already created.”

Speaking on behalf of PAI Health, Chief Commercial Officer Sally Powell said: “PAI Health’s global strategic partnership with Gen Re comes at the right time as the insurance industry is being challenged by customers to provide digital health solutions that are highly personalised and provide health protection day to day. Gen Re’s global presence combined with our unique solutions makes us ideal partners to co-develop digital insurance solutions that provide significant value to insurers and their policyholders.”

Hear more about the science behind PAI from inventor Ulrik Wisløff, Professor at NTNU and Head of the Cardiac Exercise Research Group, in conversation with Gen Re’s Ross Campbell. Link to 5 min video
PAI Health is one of a selection of hand-picked insurtech companies Gen Re is working with to develop insurance products and solutions that meet the needs and expectations of consumers in the digital age. Contact us to find out more about our digital activities and to arrange an introduction.

About Gen Re

Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. We work closely with our clients to understand their strategic and operational goals, offering a wide range of products, tools and resources that aim to promote our clients’ ongoing growth and success.

Gen Re is a member of the Berkshire Hathaway family of companies and has earned superior financial strength ratings from each of the major rating agencies. We take our commitments very seriously. With $14.4 billion in capital and $9.7 billion in premiums, we only make promises we can keep. www.genre.com

About PAI Health

PAI Health is a health technology company that offers unique data insights rooted in the proven science of cardiorespiratory fitness. The company’s suite of digital tools help insurers increase engagement, drive new customer acquisition and reduce costs. PAI (Personal Activity Intelligence) is the first scientifically validated and published score that prescribes a personalised level of activity to optimize an individual’s cardiorespiratory fitness to reduce the risk of cardiovascular and other lifestyle diseases. www.paihealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005076/en/

Contacts
Media Contact:
Sabine Denné, Head of Global Marketing & Client Communications, email: denne@genre.com

Product Contacts:
International: Ross Campbell, Life/Health Chief Underwriter R&D, email: ross_campbell@genre.com

North America: Ammon Dixon, Life/Health Strategic Initiative Projects Leader, email: ammon.dixon@genre.com

PAI Health Contact:
Tricia Burton, VP, Marketing, email: tricia.burton@paihealth.com

Permalink : https://www.aetoswire.com/news/gen-re-and-pai-health-take-strategic-partnership-to-next-level/en

Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019

LACHEN, Switzerland-Tuesday 3 December 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner (Great Ormond Street Hospital for Children, London, UK) as an oral presentation at the 61st Annual Meeting of the American Society of Hematology (ASH) 2019 in Orlando, Florida.

Dr Liesner commented that “I am excited to be representing the NuProtect study group to share these data. The data should help to inform clinical decision-making and provide valuable evidence to reassure clinicians and patients that Nuwiq® is an effective treatment option for PUPs”.

The NuProtect study is the largest prospective study of a single FVIII concentrate in true PUPs with haemophilia A. The study assessed the immunogenicity, efficacy and safety of the human cell line-derived recombinant FVIII Nuwiq® (simoctocog alfa) in 108 PUPs. Final results on the immunogenicity, efficacy and safety of Nuwiq® will be shared for the first time at an oral presentation on Monday 9th December.

“We are proud to present these important data in PUPs, which showcase the clinical features of Nuwiq® founded on its human cell line origin” said Larisa Belyanskaya, Head of IBU Haematology at Octapharma. Olaf Walter, Board Member at Octapharma, added that “The NuProtect study data add to the growing portfolio of clinical experience with Nuwiq® and support our goal at Octapharma to improve the lives of people with bleeding disorders”.

About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1. Treatment of previously untreated patients (PUPs) with Nuwiq® was assessed in the NuProtect study. In an interim analysis of 66 patients, the cumulative incidence of high-titre inhibitors was 12.8%, and the cumulative incidence of all inhibitors was 20.8%2. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations3. Nuwiq® is approved in 59 countries for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups3.

About the NuProtect study
The NuProtect study (NCT01712438) was a prospective, multicentre, multinational, open-label, non-controlled phase III study to assess the immunogenicity, efficacy and safety of Nuwiq® in patients with severe haemophilia A and without any previous exposure to FVIII concentrates or blood products containing FVIII. Patients were treated with Nuwiq® for 100 exposure days or up to 5 years. The study was conducted at 38 sites in 17 countries. A total of 110 patients were enrolled. Of these, 108 patients were treated with Nuwiq®.

About Haemophilia A
Haemophilia A is an X-linked hereditary bleeding disorder caused by a deficiency of factor VIII (FVIII) which, if left untreated, may lead to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. The disorder affects around one in every 10,000 males worldwide. Prophylaxis with replacement FVIII therapy reduces the number of bleeding episodes and the risk of permanent joint damage.

About Octapharma
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.

In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:

    Haematology (coagulation disorders)
    Immunotherapy (immune disorders)
    Critical care (bleeding management and functional volume replacement)

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.

1. Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
2. Liesner R et al. Haemophilia 2018; 24:211-20.
3. Nuwiq® Summary of Product Characteristics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005360/en/

Contacts

Octapharma AG Contacts:

Octapharma AG International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com

Larisa Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel: +41 55 4512121

Ivana Spotakova
Communications Manager
ivana.spotakova@octapharma.com
Tel.: +41793474607



Permalink : https://www.aetoswire.com/news/octapharma-announces-the-presentation-of-the-final-results-from-the-nuprotect-study-of-nuwiqreg-simoctocog-alfa-in-previously-untreated-patients-pups-at-ash-2019/en

IDEMIA to Supply Morocco’s Latest National Electronic ID Cards



COURBEVOIE, France-Saturday 30 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- IDEMIA, the global leader in Augmented Identity, has signed a strategic contract with Morocco’s Direction Générale de la Sûreté Nationale (National Security Government Department - “DGSN”) to supply the country’s latest national electronic ID cards and introduce a secured digital identity online services platform.

Backed by DGSN’s new digital identity national system, Moroccans will be able to access online services in a secured environment. IDEMIA will provide DGSN its digital authentication platform with a view to facilitating online correspondence between Moroccans and government agencies or private service providers, who seek to benefit from the new national ID card’s digital features.

The new biometric ID card will accelerate rollout of Morocco’s online services and will ramp up development of the digital economy. The card will deliver rock-solid online authentication and transaction security for all Moroccans. As a result, all online services will be able to tap into DGSN’s new digital identity national system while providing citizens user-friendly, fast and secure access that safeguards the privacy of their personal data on their electronic ID cards.

IDEMIA’s worldwide expertise helps bring about major change currently underway to introduce digital identities. IDEMIA’s solutions secure identity data in all steps involved from design and use of online and offline documents, based on extremely strict personalization and production security procedures.

IDEMIA currently produces highly secure identity documents, including national ID cards, passports, vehicle registration documents, driving licenses and healthcare cards, in countless countries around the world apart from Morocco such as the US, Estonia and the Netherlands. It also supplies comprehensive digital identity management systems to governments and public and private sector organizations.

Philippe Barreau, Executive Vice President for Public Security & Identity activities at IDEMIA, said: “Digital is a game changer for the world and what people demand. From now on, everything’s got to be faster, easier and most of all, work anywhere on a mobile device in a secured environment. The public at large have already taken on board this new way of doing things and Morocco’s government services are following this path. But e-government services will only come about if people’s physical and digital identity is fully reliable and safeguarded. Biometric technology nowadays delivers watertight security and flexibility as expected. We are proud to be able to provide Morocco our expertise and technologies.”

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191129005131/en/

Contacts

Press contact
Hanna Sebbah: +336 6373 3030
idemia@havas.com




Permalink : https://www.aetoswire.com/news/idemia-to-supply-moroccorsquos-latest-national-electronic-id-cards/en

Taulia Clients Airbus and Sasol Recognized at the 2019 Supply Chain Finance Awards

Taulia clients Airbus and Sasol were both recognized at this year’s SCF Awards.

Airbus took the category award for Transport & Logistics and the overall Gold Award for the best demonstration of SCF in action. Sasol was named the winner in the Manufacturing & Industrial category.



SAN FRANCISCO.-Saturday 30 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- The Supply Chain Finance (SCF) Awards showcase companies’ achievements in demonstrating best practice and innovation in supplier finance. Announced on 28th November at a presentation ceremony at Amsterdam’s Beurs van Berlage, this year’s SCF Awards brought double success for Taulia’s clients, with Airbus and Sasol both recognized for their considerable achievements.

Airbus not only received the category award for Transport & Logistics, but also took the Gold Award for the category-winning entry that best demonstrates SCF in action. The company’s success was richly deserved, not least because this ambitious project saw Airbus adopt a supply chain finance program that could in time be scaled across the company’s entire supply chain.

Since implementing the program, Airbus has made billions of dollars available in early payments to thousands of suppliers. The success of the project was supported by proactive measures taken by Airbus to align major stakeholders on the project, as well as by Taulia’s highly streamlined supplier onboarding process.

Sasol, meanwhile, was named the winner in the Manufacturing & Industrial category. Seeking to replace manual discounting processes and provide additional liquidity for SME suppliers, the integrated chemicals and energy company had adopted a technology-enabled dynamic discounting program provided by Taulia. As a result, the company’s early payment discount program has been scaled from 150 suppliers to almost 3,500.

In addition to capturing remarkably more early payment discounts, the program has also brought significant efficiency gains. While a team of 12 had previously been needed to handle supplier phone calls, this has been reduced to a single employee, with the others redeployed to value-adding tasks.

“This was a great night for Taulia’s clients and I am delighted to congratulate Airbus and Sasol for their achievements,” said Michael Rieskamp, Managing Director of Europe, for Taulia. “Both projects demonstrated a clear commitment to best practice and innovation, and their success is well deserved.”

Note for editors: Taulia is a leading provider of working capital solutions headquartered in San Francisco, California. Through a unique combination of its AI-powered platform, people and process, Taulia helps companies access the value tied up in their supply chain by transitioning from inefficient and often manual working capital management practices into technology-led, working capital optimization strategies. Taulia’s vision is to create a world where every business thrives and by enabling buyers and suppliers to choose when to pay and get paid, it liberates cash across the supply chain. A network of 1.8 million businesses use Taulia’s technology and the company processes over $300 billion every year. Taulia is trusted by over 120 of the world’s largest companies with clients including Airbus, AstraZeneca, Nissan, Telstra, the UK Government’s Crown Commercial Services and Vodafone. Achieving revenues of $48.8 million in 2018, the company is featured in the 2019 Inc. 5000 list of the fastest-growing private companies in the U.S.



View source version on businesswire.com: https://www.businesswire.com/news/home/20191129005122/en/

Contacts

Juhie Kapoor
juhie.kapoor@taulia.com
0207 380 4542

Permalink : https://www.aetoswire.com/news/taulia-clients-airbus-and-sasol-recognized-at-the-2019-supply-chain-finance-awards/en 

Monday, December 2, 2019

Investor Tej Kohli Expands ‘Venture Philanthropy’ Into 3d-printed Bionic Arms

 The Tej Kohli Foundation is funding 3D-printed bionic arms for 10 British children from Bristol-based robotics pioneer Open Bionics.

Open Bionics is building and developing the next generation of low-cost bionic limbs that turn disabilities into superpowers.

Kohli was also an early investor in Open Bionics and advocates its superior robotics technology for improving the confidence of children.

LONDON -Saturday 30 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Investor Tej Kohli is to fund the purchase of ten bionic arms for children with limb differences in the UK. The Tej Kohli Foundation hopes that its commitment to fund arms for ten children over the next 5 months as part of its ‘Future Bionics’ program will highlight how assistive technology can substantially improve the lives and confidence of young people living with disabilities. The Tej Kohli Foundation hopes to inspire and influence other healthcare institutions to follow this lead and discover the advanced 3D-printed technology.

In England the National Health Service (‘NHS’) currently provides a single-grip myoelectric-controlled (‘myo’) prosthesis at a cost of approximately £8,000. However, the Open Bionics Hero Arm can be controlled with the electrical signals generated by a user’s muscles and has superior multi-grip functionality that enables users to perform many more everyday activities.

The Open Bionics Hero Arm costs £10,000 through a private prosthetics clinic in the UK, whereas other advanced multi-grip bionic hands cost £30,000 - £60,000. The Tej Kohli Foundation will spend an initial £100,000 to launch its ‘Future Bionics’ programme, which will enable ten British children to access not just a superior technology, but a better life.

The first Hero Arm recipient is 10-year-old Jacob Pickering from Blackburn, who will receive his new Hero Arm just in time for Christmas. Jacob was born without his right arm as a result of amniotic band syndrome. All Jacob has spoken about for the past month is the Hero Arm, and his father David is “completely overwhelmed” that Jacob has been selected for a donation and claims that it will “change Jacob’s life”. The second Hero Arm recipient is 14-year-old Harris Gribble from Exeter, who is a keen Rugby and Cricket player.

The lightweight Hero Arm is currently the only multi-grip myo prosthetic arm that is available for paediatric use. The enhanced ability of the user to be able to personalise their 3D-printed Open Bionics Hero Arm is also a huge boost to mental well-being and to perceived social acceptance. This is particularly important for younger people.

Investor Tej Kohli first discovered Bristol-based Open Bionics when he invested into ‘Rewired’, a robotics-focused venture studio ‘with a humanitarian bent’ that was a very-early backer of Open Bionics in 2017.

Tej Kohli, Co-Founder of the Tej Kohli Foundation said:

“We started the Tej Kohli Foundation in 2005 with a project to provide daily meals for 1,000 children in Costa Rica. Since then the Tej Kohli Foundation has supported projects all over the world and helped tens of thousands of people, especially those living with disability. This gift of ten bionic arms is the first project that we have ever initiated in the UK. I see it as just the beginning, and my hope is that this gift will help to highlight the positive difference that technology can make to the confidence and prospects of a younger person. We’re doing this as an example, but we hope that others will follow our lead. These technologies are now so accessible and affordable that healthcare organisations such as the NHS should do more to embrace and improve access to them for disabled young people.”

Samantha Payne, Co-Founder and COO of Open Bionics said:

“We’re really grateful to the Tej Kohli Foundation for pledging to fund advanced bionic arms for ten children in the UK. These children are amongst dozens of people with upper limb differences in the UK fundraising right now for a Hero Arm. We've worked really hard to achieve a price point for the device that is acceptable for existing NHS budgets for prosthetic provision, and we very much hope the NHS sees how helpful these devices are and will begin offering them to the people who need them.”

Children and adults with below-elbow limb differences can register their interest at www.openbionics.com.

Images and profiles of the recipients of the Hero Arms can be downloaded here: https://www.dropbox.com/sh/wakjc66nz1ljjpb/AADwtFqgu7j-xhEtTRzYuBdsa?dl=0

About Open Bionics

Open Bionics was founded in 2014 by Joel Gibbard and Samantha Payne with the goal of developing affordable, assistive devices that enhance the human body. In other words, Open Bionics turns disabilities into superpowers. The Bristol-based bionics company is known globally for using 3D printing and 3D scanning, along with some clever software and design, to make advanced, affordable and accessible bionic limbs. In May 2018, the company released the Hero Arm, the world’s first medically approved 3D-printed bionic arm, and the very first multi-grip bionic arm for children as young as eight years old. The Hero Arm is available now through private prosthetic clinics all around the world. Open Bionics have a development contract with NHS England, with the aim of offering the Hero Arm on the NHS in the UK. They also have royalty-free licensing agreements with Disney, Marvel, Lucasfilm, Eidos Montreal and Twentieth Century Fox, making science fiction a reality.

http://www.openbionics.com

About the Tej Kohli Foundation

Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness, which disproportionately impacts young people in poorer countries. Since 2015 the Foundation has funded free corneal transplants in poor communities in India; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness.

Through its ‘Impact Initiatives’ the Tej Kohli Foundation also makes direct interventions into the lives of young people whose confidence and prospects can be substantially improved. Previous ‘Impact Initiatives’ have included financial support for disabled children in Costa Rice, feeding schoolchildren at after-school clubs in poor communities, and also producing a short film to highlight the plight of young people in India living with a rare genetic disease.

http://www.tejkohlifoundation.com

About Tej Kohli

Tej Kohli is a London-based investor and philanthropist who first rose to success selling technology solutions and payments software during the dot com boom. His current focus is as a real estate investor within the world’s newly emerging technology hubs, and as a backer of high-impact AI, robotics and genomics ventures that have the potential to transform lives and change the world. He is also a major esports investor.

Tej Kohli is a distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.

http://www.tejkohli.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20191128005558/en/

Contacts

To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
kohliventures@buchanan.uk.com
+44 207 466 5000

Permalink : https://www.aetoswire.com/news/investor-tej-kohli-expands-lsquoventure-philanthropyrsquo-into-3d-printed-bionic-arms/en